Guillain-Barre syndrome and Campylobacter jejuni infection

Summary, 145S 2. Int0roduction, 145S 3. Guillain–Barré syndrome, 145S 3.1 Clinical features, 145S 3.2 Pathology, 146S 3.3 Epidemiology, 146S 4. Autoimmune pathogenesis of Guillain–Barré syndrome, 146S 4.1 Preceding infections, 146S 4.2 Mechanism of pathogenesis, 146S 4.3 Animal models of autoimmune neuropathy, 148S 4.4 Immunogenetic factors, 148S 5. Association between Guillain–Barré syndrome and Campylobacter jejuni infection, 148S 6. Campylobacter jejuni and antibodies to ganglioside GM1, 148S 6.1 Gangliosides, 148S 6.2 Antibodies to gangliosides in GBS, 149S 6.3 Epidemiological association of C. jejuni and antibodies to ganglioside GM1, 149S 6.4 Molecular mimicry, 149S 6.4.1 2Structural mimicry, 149S 6.4.2 Antibody cross‐reactivity, 150S 6.4.3 T cell receptor cross‐reactivity, 150S 6.5 Limitations of molecular mimicry hypothesis, 150S 7. Campylobacter jejuni and neurophysiological subtypes of Guillain–Barré syndrome, 150S 8. Campylobacter jejuni and poor outcome in Guillain–Barré syndrome, 151S 8.1 Causes of poor outcome, 151S 8.2 Treatment, 151S 9. Conclusions, 151S 10. References, 152S